Researchers developed the crossNN AI model that classifies over 170 cancer types from DNA methylation data, achieving over 97% accuracy and enabling non-invasive diagnosis from liquid biopsies and tissue samples.
Key Details
- 1crossNN is a simple, explainable neural network AI trained on 8,000+ reference tumors and tested on 5,000+ tumors.
- 2Achieved 99.1% accuracy for brain tumor diagnosis; 97.8% accuracy across more than 170 tumor types from all organs.
- 3Uses DNA methylation profiles obtained from tissue or body fluids (e.g., cerebrospinal fluid), enabling some diagnoses to avoid surgical biopsies.
- 4Proven more accurate than previous AI solutions for tumor classification.
- 5The method is being prepared for clinical trials at all eight sites of the German Cancer Consortium.
- 6crossNN's workflow is fully explainable, meeting a key regulatory requirement for clinical adoption.
Why It Matters
crossNN demonstrates the potential of AI-driven, minimally invasive tumor diagnostics, which could complement imaging in cases where biopsy is too risky or impractical. Such models can improve diagnostic precision, reduce patient morbidity, and streamline selection of personalized treatments, impacting radiology workflows and multidisciplinary cancer care.
Source
EurekAlert
Related News
•EurekAlert
USC Unveils Joint Biomedical Engineering Department Bridging Medicine, Engineering, and Imaging
USC's medical and engineering schools launch a joint biomedical engineering department to accelerate interdisciplinary research and innovation, including imaging and AI.
•EurekAlert
AI Predicts Risks for Outpatient Stem Cell Therapy in Myeloma
Researchers use machine learning to predict adverse events during stem cell therapy for multiple myeloma, improving outpatient safety.
•EurekAlert
AI-Enhanced CT Heart Fat Measurement Boosts Cardiovascular Risk Prediction
AI-derived measurement of heart fat from CT scans significantly improves long-term cardiovascular disease risk prediction.